MUSTANG BIO, INC.MBIO

時価総額

$477.2万

PER

臨床段階のバイオ医薬品開発の新興企業。CAR-T療法やオンコリティックウイルスを活用した治療候補を展開。主要株主が議決権の過半数保有、2024年5月13日にCFIUSとのNSA締結で取引中止、2024年6月27日に資産再取得。米国中心に展開。

概要財務

サマリーテーブルに戻る

	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net loss	-13	-31	-31	-46	-60	-66	-78	-52	-16
Issuance of Common Shares Equity Fee on Equity Offering	-	-	-	-	-	-	-	-	0
Common Shares Issuable Annual Stock Dividend	-	-	-	-	-	-	-	-	1
Research and development - licenses acquired	-	-	-	1	2	2	0	0	0
Stock-based compensation expenses	-	2	5	3	3	3	2	1	-0
Depreciation	-	0	1	1	2	2	3	2	1
Amortization of debt discount	1	-	-	1	2	-	0	0	-
Amortization of operating lease right-of-use assets	-	-	-	-	-	0	0	0	0
Loss on disposal of property and equipment	-	-	-	-	-	-	-	-	-0
Asset impairment	-	-	-	-	-	-	-	-	4
Gain on sale of property and equipment	-	-	-	-	-	-	-	1	-
Loss on extinguishment of debt	-	-	-	-	-	-	-	-3	-
Gain on lease modification	-	-	-	-	-	-	-	-0	0
Prepaid expenses and other assets	-	-	-	1	0	0	1	-1	-1
Related Party	-	-	-	-	-	-	-	-0	-
Non related party	-	-	-	-	-	-	-	4	-0
Other receivables	-	-	-	0	-0	0	-0	-	-
Accounts payable and accrued expenses	-	-	-	0	3	-0	5	0	-3
Payable and accrued expenses - related party	-0	0	0	0	-0	0	0	0	2
Deferred income	-	-	-	-	-	0	-	-	-0
Lease liabilities	-	-	-	-0	-0	0	0	1	0
Net cash used in operating activities	-	-13	-19	-34	-37	-54	-65	-49	-11
Purchase of research and development licenses	-	2	1	1	2	1	0	0	-
Proceeds from the sale of property and equipment	-	-	-	-	-	-	0	6	-
Purchase of fixed assets	-	-	7	2	2	4	3	0	-
Net cash from investing activities	-	-29	1	14	-4	-5	-3	6	-
Payment of debt	-	-	-	-	-	-	-	30	-
Proceeds from Issuance of Common Stock	-	-	-	32	37	-	-	-	7
Offering costs for the issuance of common shares - Equity Offerings	-	-	-	2	2	-	-	-	1
Proceeds from issuance of common shares - At-the-Market Offering	-	-	-	23	60	72	7	0	3
Offering costs for the issuance of common shares - At-the-Market Offering	-	-	-	1	1	1	0	0	0
Proceeds from Warrant Exercises	-	-	0	-	-	-	-	-	4
Proceeds from Stock Plans	-	-	-	-	0	0	0	0	0
Net cash provided by (used in) financing activities	-	50	0	65	78	71	34	-26	11
Net change in cash, cash equivalents and restricted cash	-	-	-	45	36	12	-34	-70	-0
Cash paid for interest	-	0	-	1	2	-	3	1	-
Stock Issued	0	4	10	2	5	8	4	1	1